---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-137119"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:43:55.721580+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# All nine proposals approved at NewAmsterdam Pharma 2025 AGM

## Summary
- Quorum of 83.6M ordinary shares (74.45%) voted; all nine agenda items passed.
- Dutch statutory annual accounts for FY2024 approved: 83.5M for, 5.6K against.
- Three non-executive directors (Joustra, McKenna, Gulfo) each elected with >79M for votes.
- Michael Davidson reappointed executive director (70.5M for, 9.2M against); James Topper reappointed non-executive.
- Share buyback authorization extended (71.4M for, 12.2M against); say-on-pay approved and set for annual frequency.

## SEC filing metadata
- accession: 0001193125-25-137119
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525137119/0001193125-25-137119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525137119/d933201d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-137119
- JSON: https://secwatch.observer/filing/0001193125-25-137119.json
- Plain text: https://secwatch.observer/filing/0001193125-25-137119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.